

**Data Dictionary for SWOG S0819 Clinical Dataset
(NCT00946712-D1-Dataset.csv)**

Variable Name	Variable Description	Type	Code	Code Definition
ALTPATID	Pseudo patient ID	Char		
AGE	Age at randomization, years	Num		Number
SEX	Sex	Char	F	Female
			M	Male
RACE	Race	Char	A	Asian
			B	Black
			N	Native American
			P	Pacific Islander
			U	Unknown
			W	White
HISPANIC	Hispanic ethnicity	Char	Y	Yes
			N	No
			U	Unknown
SMOKE_CUR	Smoking history: current	Num	0	No
			1	Yes
SMOKE_FOR	Smoking history: former	Num	0	No
			1	Yes
SMOKE_NEV	Smoking history: never	Num	0	No
			1	Yes
STAGE_M1B	M-stage	Num	0	M1a
			1	M1b
BEV	Bevacizumab treatment	Num	0	Did not receive Bevacizumab
			1	Received Bevacizumab
HISTNSCL	NSCL histology	Num	1	Squamous cell carcinoma
			2	Adenocarcinoma
			3	Large-cell carcinoma
			4	Bronchioloalveolar carcinoma
			5	Mixed \geq 50% squamous
			6	Mixed $<$ 50% squamous
			7	Other
			9	Not reported
SCCA	Squamous cell histology	Num	0	Non-squamous histology
			1	Squamous cell histology
PS	Performance status- Zubrod scale	Num	0	Fully active
			1	Restricted
			2	Ambulatory, but unable to work
			9	Missing data
FISH	EGFR FISH status	Num	1	FISH negative
			2	FISH positive

			3	FISH assay failed
			4	Specimen inadequate for FISH
			9	missing data
INELIGIBLE	Eligibility flag	Num	0	Eligible
			1	Ineligible
INELIG_RSN	Reason for ineligibility	Char		Text [Note: " " = > NA]
ARMC	Treatment arm	Char	Cetuximab Arm	Cetuximab Arm
			Control Arm	Control Arm
TRNO	Treatment number	Num	1	Control arm
			2	Cetuximab arm
DISEV	Disease evaluation	Char	MBL	Measurable disease
			RNM	Non-measurable RECIST
CLINTOX	Clinical toxicity evaluation	Char	Y	Evaluable
			N	Not evaluable
RXSTAT	Treatment status/ reason off treatment	Char	COMP	Completed treatment as planned
			DEAD	On study death
			ON	On treatment
			OTH	Other
			PROG	Progression
			REF	Refused further treatment
PRGREL	Progression/relapse status	Char	Y	Yes
			N	No
RESP4	Best response on treatment	Char	CR	Complete response
			ED	Early death
			INC	Increasing disease
			NA	not applicable
			NASS	No assessment
			NASSD	Inadequate, delinquent
			NASSF	Inadequate, no follow up
			NASSI	Inadequate, inconsistent
			NASSN	Inadequate, not assessed
			PR	Partial response
			STA	Stable/no response
			SYMP	Symptomatic deterioration
UCR	Unconfirmed complete			

				response
			UPR	Unconfirmed partial response
RESPONSE	Any complete, partial, unconfirmed complete or unconfirmed partial response?	Num	0	No
			1	Yes
			“ ”	NA [Patient was not evaluable for response]
PROG	Progression-free survival	Num	0	Censored
			1	PFS event
PFSTIM	Progression-free survival time, months	Num		
SURIND	Overall survival indicator	Num	0	Alive
			1	Dead
SURTIM	Overall survival time, months	Num		
FISH_POS	EGFR FISH results	Num	0	Non-positive (negative, unknown)
			1	Positive
REDUCE	At least one dose reduction of study drugs	Num	0	No
			1	Yes
DEV_ANY	Any treatment deviations	Num	0	No
			1	Yes
DEV_NOTX	Deviations: did not receive treatment	Num	0	No
			1	Yes
DEV_CARBO	Deviations: carboplatin dosing error	Num	0	No
			1	Yes
DEV_BEV	Deviations: treated with bevacizumab when medically contraindicated	Num	0	No
			1	Yes
DEV_OTH	Deviations: other	Num	0	No
			1	Yes
POST_PEM	Post-progression pemetrexed	Char	0	No
			1	Yes
POST_ERLOT	Post-progression erlotinib	Num	0	No
			1	Yes
POST_GEF	Post-progression gefitinib	Num	0	No
			1	Yes
POST_OTH	Other post-progression therapy	Num	0	No
			1	Yes
ANY_POST	Any post-progression therapy	Num	0	No
			1	Yes

NOTE: Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning). In addition, there is a typographical error in table 1 for which an erratum is being submitted to the publication.